Home

News:

Dr. Larn Hwang, CEO, will conduct two presentations titled ‘Cytokine Induction by Trabedersen (OT-101) Treatment – Results from a Phase I/II Trial in Pancreatic Cancer Patients’ on September 4th, 2016 at the 43rd International Society of Oncology and Biomarkers (ISOBM) Congress in Chicago, IL and ‘Impact of Antisense OT-101 Therapy on the Cytokine and Chemokine Profile in Patients with Pancreatic Cancer’ on September 26th, 2016 at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal, Canada.

Dr. Larn Hwang, CEO, will be presenting the poster entitled “Treatment with Trabedersen- an anti-TGF-beta-2 antisense- primed tumors to subsequent chemotherapies” at The 3rd St. Gallen International Gastrointestinal Cancer Conference, St. Gallen, Switzerland.

Learn More >>

Autotelic

IthenaPharma

Stocosil

Lipomedics